These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3447702)

  • 41. Influence of isosorbide-5-mononitrate on the circadian rhythm of angina pectoris.
    Ganzinger U
    Arzneimittelforschung; 1992 Mar; 42(3):307-10. PubMed ID: 1497689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isosorbide mononitrate for angina.
    Med Lett Drugs Ther; 1992 Jun; 34(873):61. PubMed ID: 1608345
    [No Abstract]   [Full Text] [Related]  

  • 43. [Isosorbide 5-mononitrate (delayed release) in stable effort angina].
    Almenar Bonet L; Miró Palau V; Gimeno Gascón JV; Algarra Vidal F
    Rev Esp Cardiol; 1992; 45(7):456-61. PubMed ID: 1439070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide 5-mononitrate at low doses in patients with coronary heart disease.
    Uberbacher HJ; Steinorth G; Glocke M; Abshagen U
    Pharmatherapeutica; 1983; 3(5):331-41. PubMed ID: 6342004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Influence of isosorbide-5-mononitrate on the tolerance test to exertion in angina pectoris].
    Cherchi A; Lai C; Onnis E; Cherchi A; Meloni L; Pirisi R
    Cardiologia; 1985 Jun; 30(6):439-48. PubMed ID: 3833355
    [No Abstract]   [Full Text] [Related]  

  • 46. Development of long-acting nitrate delivery systems.
    Jonsson UE
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S15-9. PubMed ID: 2113000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hemodynamic effects of isosorbide-5-mononitrate in ischemic cardiopathy].
    Russo G; Tolaro S; Monaco O; Greco G; Grassi R; Monaco A; Calvi V; Felis S; Tamburino C; Giuffrida G
    Cardiologia; 1988 Mar; 33(3):291-5. PubMed ID: 3401892
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effectiveness of the delayed-action form of isosorbide 5-mononitrate in ischemic heart disease].
    Hůla J; Trhlíková M
    Vnitr Lek; 1991 Mar; 37(3):248-54. PubMed ID: 2031313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacokinetics and bioavailability of a new slow-release isosorbide-5-mononitrate system].
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Cardiologia; 1987 Nov; 32(11):1287-91. PubMed ID: 3447701
    [No Abstract]   [Full Text] [Related]  

  • 50. [Studies on isosorbide dinitrate. II. Determination of isosorbide 5-mononitrate in human plasma and pharmacokinetics].
    Sugiyama T; Yasuda K; Imaeda N; Furuzawa T; Yamazoe K; Mizukami Y
    Yakugaku Zasshi; 1987 Jan; 107(1):65-9. PubMed ID: 3585710
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparison of steady state pharmacokinetics of isosorbide-5-mononitrate in microgranular formulation or hydrophilic matrix].
    Centonze F; Brambilla M; Pittana P; Serra G; Sega R
    Clin Ter; 1988 Aug; 126(3):195-206. PubMed ID: 2974386
    [No Abstract]   [Full Text] [Related]  

  • 52. [Quality of life of patients with ischemic heart disease taking isosorbide-5-mononitrate in an outpatient setting].
    Popov KV; Kuimov AD
    Kardiologiia; 2003; 43(7):53-4. PubMed ID: 14603907
    [No Abstract]   [Full Text] [Related]  

  • 53. [Slow-release nitrates: a critical review].
    Ambrosioni E; Strocchi E
    Cardiologia; 1987 Nov; 32(11):1283-6. PubMed ID: 3129193
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy of isosorbide-5-mononitrate in the prevention of myocardial ischemia induced by ergonovine and by hand-grip tests.
    Distante A; Lombardi M; Moscarelli E; Morales MA; Sabino F; L'Abbate A
    Z Kardiol; 1985; 74 Suppl 4():25-31. PubMed ID: 4096068
    [No Abstract]   [Full Text] [Related]  

  • 55. Emergency treatment of severe cardiogenic pulmonary edema with intravenous isosorbide-5-mononitrate.
    Harf C; Welter R
    Am J Cardiol; 1988 Mar; 61(9):22E-27E. PubMed ID: 3348137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapeutic effectiveness of isosorbide-5-mono nitrate in the treatment of exertion myocardial ischemia].
    Cassottana P; Torre F; Bafico GL; Oddone D; Vinci P; Gatto R; Borgo E
    Minerva Cardioangiol; 1987; 35(1-2):79-82. PubMed ID: 3561813
    [No Abstract]   [Full Text] [Related]  

  • 57. A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations.
    Verma RK; Garg S
    J Pharm Biomed Anal; 2002 Oct; 30(3):583-91. PubMed ID: 12367683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pituitary apoplexy following isosorbide administration.
    Bevan JS; Oza AM; Burke CW; Adams CB
    J Neurol Neurosurg Psychiatry; 1987 May; 50(5):636-7. PubMed ID: 3585391
    [No Abstract]   [Full Text] [Related]  

  • 59. [Pharmacokinetics of isodinit (from Pharmachem) in humans].
    Georgieva R; Ognianova V; Velikova E; Naplatanova D; Mikhaĭlova D
    Eksp Med Morfol; 1984; 23(3):138-43. PubMed ID: 6519014
    [No Abstract]   [Full Text] [Related]  

  • 60. New development in nitrate drugs.
    Miller CA
    Geriatr Nurs; 1992; 13(5):287. PubMed ID: 1327996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.